These data suggest that complete and not partial p-NTRK inhibition is necessary to block tumor growth, and that merestinib, a type II NTRK kinase inhibitor may have an advantage over type I NTRK kinase inhibitors in durability of treatment response in patients. Here, SGCG is linked to neoplasm.